Ionis' Latest Attempt To Weaponize Antisense Against Cancer Seeking Alpha, 15 Mar 2017 Ionis (NASDAQ: IONS ) quietly added KRAS-mutant cancers to its list of generation 2.5 ASO (antisense oligonucleotide) targets.